Anavex Life Sciences Corp (AVXL)

[sokol]

I have long thought that seeking approval for Blarcamesine in Europe first is the best strategy for Anavex. The EMA is concerned about cost and has been leery of the side effects of Leqembi and its administration. However, Europe is in great need of a potentially treatment option for AD that may benefit the European healthcare system and potentially lower the cost for DD patients. The following language from today’s PR is key:

“…for convenient oral treatment options for Alzheimer’s disease not requiring complex logistics resources and added personnel for drug administration and monitoring for brain edema and brain bleeds.

Severe symptoms in relation to Amyloid-Related Imaging Abnormalities (ARIA) is a known risk factor for Alzheimer’s patients taking the class of drugs called monoclonal antibodies, and requires constant and repeated MRI examination, for which not all regions in Europe are currently sufficiently prepared and equipped for in addition to the requirement to address affordability and inequalities in patient access within European Union countries.”